Program
Fluorouracil
Also written as “5-Fluorouracil”, “fluorouracil” and “5-fluorouracil”.
Its studies are mostly in Colorectal Neoplasms · Pancreatic Neoplasms · Neoplasms · Head and Neck Neoplasms · Stomach Neoplasms, led by 12 companies.
Drug pageFluorouracil: every studyMany companies study it; this page follows only the 34 they lead. All 763 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 160 open or running | phase 4since Sep 14, 2006 | Jan 6, 2001 | none ahead |
| Pfizerits history only | 51 open or running | phase 3since Jan 28, 2000 | Jan 28, 2000 | none ahead |
| Jiangsu HengRui Medicineits history only | 21 open or running | phase 3since Feb 20, 2023 | Mar 8, 2021 | none ahead |
| Otsukaits history only | 20 open or running | phase 3since Jun 2, 2000 | Jun 2, 2000 | none ahead |
| Prologue Research Internationalits history only | 20 open or running | phase 3since Jun 5, 2003 | May 6, 2001 | none ahead |
| Almirall | 10 open or running | phase 3since Nov 10, 2014 | Nov 10, 2014 | none ahead |
| CbsBioscienceits history only | 10 open or running | phase 2since Nov 10, 2016 | Nov 10, 2016 | none ahead |
| Encube Ethicals Pvt.its history only | 10 open or running | phase 3since Sep 23, 2021 | Sep 23, 2021 | none ahead |
| HealthCare Global Enterpriseits history only | 10 open or running | phase 2since Sep 29, 2016 | Sep 29, 2016 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 3since Feb 25, 2019 | Feb 25, 2019 | none ahead |
| Sol-Gel Technologiesits history only | 10 open or running | phase 3since Oct 30, 2018 | Oct 30, 2018 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 3since Nov 25, 2015 | Nov 25, 2015 | none ahead |
Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Ono Pharmaceutical, Merck KGaA, Darmstadt, Germany, Eli Lilly, Parexel, Halozyme Therapeutics, BioLineRx, Baili-Bio (Chengdu) Pharmaceutical, Quintiles, Takeda, Almirall Hermal and Regeneron Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Almirall only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 10, 2014First study: phase 3 study in Keratosis, ActinicFirst studyNCT02289768 · 166 enrolled · Germany, United Kingdom
TargetBeta
“Thymidylate synthase inhibitor; RNA inhibitor”ChEMBL 37, by rule
Other programs on TYMS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Pemetrexedrule | Eli Lilly | phase 4 | 141 |
| Capecitabinerule | Hoffmann-La Roche | phase 4 | 129 |
| Tegafurrule | Otsuka | phase 3 | 25 |
Studies
The one study Almirall leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02289768Keratosis, Actinic · Germany, United Kingdom | 3 | Completed | Sep 2015 | 166 |
How it is read
Names in the registry
- “5-Fluorouracil”, 10 entries
- “fluorouracil”, 9 entries
- “Fluorouracil”, 8 entries
- “5-fluorouracil”, 7 entries
- “5-FU”, 5 entries
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 18 studies
- Pancreatic Neoplasms, 9 studies
- Neoplasms, 7 studies
- Head and Neck Neoplasms, 7 studies
- Stomach Neoplasms, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.